SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) shares were up 1.6% during mid-day trading on Wednesday . The stock traded as high as $1.38 and last traded at $1.31. Approximately 1,674,518 shares changed hands during trading, an increase of 23% from the average daily volume of 1,365,601 shares. The stock had previously closed at $1.29.
SELLAS Life Sciences Group Price Performance
The stock has a market capitalization of $127.19 million, a price-to-earnings ratio of -2.03 and a beta of 2.53. The firm has a 50-day moving average of $1.18 and a 200 day moving average of $1.16.
SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03. During the same period last year, the company posted ($1.34) EPS. On average, equities analysts forecast that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current year.
Institutional Trading of SELLAS Life Sciences Group
Several hedge funds and other institutional investors have recently modified their holdings of SLS. Brooklyn FI LLC acquired a new stake in SELLAS Life Sciences Group in the 4th quarter worth about $677,000. Anson Funds Management LP increased its position in SELLAS Life Sciences Group by 50.2% during the 4th quarter. Anson Funds Management LP now owns 1,192,266 shares of the company's stock worth $1,240,000 after purchasing an additional 398,431 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of SELLAS Life Sciences Group by 21.2% in the 4th quarter. Geode Capital Management LLC now owns 733,546 shares of the company's stock valued at $763,000 after acquiring an additional 128,355 shares during the last quarter. State Street Corp boosted its stake in shares of SELLAS Life Sciences Group by 30.2% during the third quarter. State Street Corp now owns 174,529 shares of the company's stock valued at $218,000 after purchasing an additional 40,500 shares in the last quarter. Finally, Northern Trust Corp boosted its position in SELLAS Life Sciences Group by 33.6% during the 4th quarter. Northern Trust Corp now owns 134,721 shares of the company's stock worth $140,000 after buying an additional 33,878 shares during the period. Institutional investors own 17.38% of the company's stock.
About SELLAS Life Sciences Group
(
Get Free Report)
SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Featured Articles
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
